Alcohol Use Disorder (AUD) Market to Witness Growth Across the APAC Region During the Forecast Period, Estimates DelveInsight | Adial Pharmaceuticals, Bioprojet, Dicerna Pharma, Gilead, MediciNova, Opiant Pharmaceuticals, Organon, Pfizer, and R-Pharm

DelveInsight's "Alcohol Use Disorder (AUD) - Patient Pool Analysis, Market Size, and Market Forecast APAC, 2034" report provides comprehensive insights into the historical and projected patient burden, treatable patient population, and notable market trends across the APAC region (India, China, South Korea, Taiwan, and Australia), highlighting distinctions from established markets.

The APAC Alcohol Use Disorder market report also offers insights into current treatment patterns, emerging prominent players, market shares of approved drugs, and peak share estimates for upcoming therapies. It covers historical and forecasted Alcohol Use Disorder market size, share, and trends in the Asia-Pacific region (India, China, South Korea, Taiwan, and Australia) during the study period (2020-2034). Additionally, the report examines recent treatment practices, therapy compliance, and accessibility, identifying unmet needs and evaluating market potential.

Alcohol Use Disorder (AUD): An Overview
Alcohol use disorder (AUD) is one of the most common substance use disorders characterized by excessive, uncontrollable drinking that impacts a person physically, emotionally, and socially. It can be mild, moderate, or severe, based on the number of symptoms experienced by an individual. A person with AUD may experience both intoxication and withdrawal symptoms such as unstable moods, poor judgment, slurred speech, problems with attention or memory, poor coordination, sweating, rapid heartbeat, hand tremors, seizures, etc.

It has multiple causes, with genetic, physiological, psychological, and social factors all impacting an individual's behavior. Healthcare professionals use the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criteria to diagnose and determine the severity of AUD and it requires that at least two of the 11 DSM-V diagnostic criteria are present to confirm the diagnosis.

Alcohol Use Disorder Market Outlook (APAC Region)
The market for Alcohol Use Disorder (AUD) in the Asia Pacific region is undergoing significant changes, driven by heightened recognition of its public health impact. AUD, characterized by problematic alcohol consumption, is increasingly acknowledged as a pressing issue. Traditional treatment methods include counseling and medication, but there's a shift towards more tailored interventions and holistic care approaches. Awareness campaigns and digital health solutions are expanding access to treatment and support services, while collaboration among stakeholders is essential for effective prevention and intervention strategies. Challenges such as cultural norms and limited access to specialized care persist, but efforts are underway to address these barriers. Overall, there's a growing momentum towards comprehensive approaches aimed at reducing the burden of AUD and improving outcomes for affected individuals in the region.

Get a Detailed Overview of the Evolving Alcohol Use Disorder Market Trends @
https://www.delveinsight.com/report-store/alcohol-use-disorder-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alcohol Use Disorder (AUD) Market
The Alcohol Use Disorder Market is poised for significant evolution, particularly within Asia-Pacific countries. This shift is underscored by the market outlook section of the report, which aims to enhance comprehension by delving into historical, present, and forecasted market projections. By examining the influence of both markets and emerging therapies, the report offers insights into the transformative forces at play. Furthermore, it conducts a thorough examination of the drivers, barriers, unmet needs, and emerging technologies within the Alcohol Use Disorder market landscape.

The report comprehensively outlines the market trends associated with every Alcohol Use Disorder drug currently available in the market and those in late-stage pipeline (i.e. Phase III stage) development. This thorough analysis encompasses various facets such as the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MOA), competitive landscape vis-à-vis other therapies, brand reputation, and their overall influence on the market dynamics. Furthermore, it incorporates insights from key opinion leaders, providing a holistic view of the market scenario.

Homozygous Familial Hypercholesterolemia (HoFH) Market Outlook (APAC Region)

Discover How the Alcohol Use Disorder Market Will Grow by 2034 @
https://www.delveinsight.com/report-store/alcohol-use-disorder-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alcohol Use Disorder (AUD) Epidemiology
The prevalence of Alcohol Use Disorder differs significantly across the APAC countries (India, China, South Korea, Taiwan, and Australia), influenced by a multitude of factors including genetics, demographics, lifestyle choices, and environmental elements. Within the report's epidemiology section, a comprehensive examination of patient burdens within each Asia-Pacific country is provided, encompassing historical, present, and projected trends. This analysis not only addresses the diagnosed and treated patient populations but also delves into sub-segments such as age-specific and gender-specific demographics, offering a nuanced understanding of the disease landscape within the region.

The Report Covers the Alcohol Use Disorder Epidemiology Segmented as -
• 12-month Diagnosed Prevalent Cases of AUD in the ASIA Pacific Region
• Type-specific Diagnosed Prevalent Cases of AUD in the ASIA Pacific Region
• Gender-specific Diagnosed Prevalent Cases of AUD in the ASIA Pacific Region

Get Key Insights Into the Evolving Alcohol Use Disorder Epidemiology Trends @
https://www.delveinsight.com/report-store/alcohol-use-disorder-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alcohol Use Disorder Drugs Uptake and Pipeline Development Activities
Numerous leading pharmaceutical and biotechnology firms are actively engaged in developing therapies for Alcohol Use Disorder. This section of the Alcohol Use Disorder market report offers detailed insights into each therapy approved within the APAC countries, provided the therapy retains patent protection or market exclusivity in at least one APAC nation. Notably, off-label, generic, and biosimilar treatments are consolidated within the preceding treatment section of the report. Within this section, both marketed and late-stage (Phase III and Phase II) pipeline drugs are scrutinized, while early-phase drugs are presented in tabular format for clarity and accessibility.

Every Alcohol Use Disorder drug chapter within the report will encompass a comprehensive overview, comprising detailed descriptions, clinical trial evaluations, insights into research and development initiatives, as well as analyses of agreements and collaborations pertinent to each drug. Moreover, the chapters will delve into approval status, patent particulars, and a thorough examination of the advantages and disadvantages associated with each drug. Additionally, the report covers the latest updates and news pertaining to each product, ensuring a well-rounded understanding of the current landscape surrounding these therapies.

Explore More About Ongoing Pipeline Development Activities in the Alcohol Use Disorder Market @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Alcohol Use Disorder Therapeutics Assessment
The trajectory of alcohol use from occasional, through habitual to daily is a complex interplay between genetic vulnerabilities, environmental factors, and habitual and learned behaviors. Management of patients presenting with AUD has to be tailored depending on the presenting complaint, the level and duration of use, the severity of dependence, the presence of any additional comorbid substance use disorders, and the current physical and/or mental health conditions along with the motivation to change.

Management always needs to start with the engagement of the patient in the process and understanding their initial goals for treatment. Following this, the focus of treatment may be on reduction of use, medically assisted withdrawal (detoxification or 'detox'), or relapse prevention

The main goal of AUD treatment is either complete abstinence or reduction of heavy drinking (harm reduction), which is a proxy marker for harmful alcohol-related psychosocial consequences. Although controversy exists as to which is the preferred goal of AUD treatment, both options have benefits. The mainstay of AUD treatment is psychosocial intervention. However, unfortunately, the relapse rate is higher with psychosocial intervention alone as compared to in combination with pharmacotherapy.

Several major pharma and biotech companies are currently engaged in the development of therapies for Alcohol Use Disorder (AUD). Among these companies, some have progressed their AUD drug candidates to the most advanced stage of development, namely Phase III clinical trials. Notably, Adial Pharmaceuticals stands out as one of the companies with drug candidates in this advanced stage. Adial Pharmaceuticals' focus on Phase III trials underscores its dedication to bringing potential treatments for AUD to market, addressing a critical public health issue. Additionally, there are several other pharmaceutical and biotech companies actively involved in advancing their AUD drug candidates, collectively contributing to the growing arsenal of therapeutic options for individuals struggling with alcohol dependence.

Leading Companies in the Alcohol Use Disorder Therapeutics Market Include
ADial Pharmaceuticals, Arbor Pharmaceuticals, Bioprojet, Confluence Pharmaceuticals, Corcept Therapeutics, Dicerna Pharmaceuticals, Inc., Gilead Sciences, Kinnov Therapeutics, Laboratorio Farmaceutico, MediciNova, Opiant Pharmaceuticals, Organon, Pfizer, and R-Pharm | Synergy Research are among the pharmaceutical companies involved in developing therapies for the treatment of Alcohol Use Disorder.

Emerging and Marketed Alcohol Use Disorder Therapies Covered in the Report Include
• ANS-6637: Amygdala Neurosciences
• CORT118335 (mifepristone): Corcept Therapeutics
• GET73: Laboratorio Farmaceutico
• Ketamine: Awakn Life Sciences
• MN-166 (ibudilast): MediciNova
• Ondansetron: Adial Pharmaceuticals
• PT150: Pop Test Oncology
And Many Others

Learn More About the Emerging Therapies and key Companies in the Alcohol Use Disorder Therapeutics Market @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content (TOC)
1. Key Insights
2. Report Introduction
3. Market Overview at a Glance
4. Epidemiology and Market Methodology
5. Executive Summary
6. Key Events
7. Alcohol Use Disorder Disease Background and Overview
8. APAC Alcohol Use Disorder Patient Pool Analysis
9. APAC Alcohol Use Disorder Patient Journey
10. Marketed Alcohol Use Disorder Therapies
11. Emerging Alcohol Use Disorder Therapies
12. Alcohol Use Disorder APAC Market Analysis
13. Access and Reimbursement Scenario
14. KOL's Views on Alcohol Use Disorder Market
15. SWOT Analysis
16. Unmet Needs
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
*The table of contents is not exhaustive; the final content may vary.

Download the Sample PDF to Get Detailed Insights About the Report's Offerings @
https://www.delveinsight.com/sample-request/alcohol-use-disorder-market-size-and-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Contact Info:
Shruti Thakur
Manager (Marketing & Branding)
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.